Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...
When your garden entrance has better curb appeal than most people’s entire front yards combined. Photo credit: Elizabethan ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ; Additional data from ADAPT SERON ...
Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...
Nivolumab combined with AVD demonstrated superior progression-free survival compared with brentuximab vedotin with AVD in advanced classical Hodgkin lymphoma (cHL). The SWOG S1826 trial showed a ...
Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients treated with sutimlimab, with an average treatment ...
SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...
The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results